Printer Friendly

WARNER-LAMBERT'S ACCUPRIL CLEARED FOR TREATMENT OF HEART FAILURE

 MORRIS PLAINS, N.J., Nov. 3 /PRNewswire/ -- Warner-Lambert Company (NYSE: WLA) today said the U.S. Food and Drug Administration has granted expanded labeling for Accupril (quinapril hydrochloride tablets) as adjunctive therapy for the treatment of congestive heart failure (CHF). The drug, currently marketed in the U.S. for the treatment of hypertension, was unanimously recommended for clearance by an FDA advisory committee in February.
 An ACE (angiotensin-converting enzyme) inhibitor developed by the company's Parke-Davis division, Accupril is available for use in more than 40 countries, mostly for the treatment of both hypertension and CHF. It received marketing clearance in the U.S. in November, 1991, and has become the fastest-growing ACE inhibitor. Through the first nine months of 1993, Accupril had worldwide sales exceeding $120 million.
 Joseph E. Smith, president of Warner-Lambert's Pharmaceutical Sector, said, "Accupril has gained acceptance in the medical community for hypertension because our clinical experience has shown Accupril can control more patients by raising the dose without an increase in dose- related side effects. Furthermore, the dose can be increased at no further cost to the patient because Accupril has a policy of one price for all strengths."
 "The clearance for CHF is an important event for Accupril, since it joins only three other ACE inhibitors indicated for CHF," Smith said. "This will further enhance the formulary acceptance of Accupril, which is already strong in the managed care community."
 ACE inhibitors comprise the fastest growing segment among CHF therapies. According to the American Heart Association, as many as three million Americans suffer from CHF, a condition that occurs because the heart muscle is damaged or overworked. During 1992, sales of ACE inhibitors reached $5 billion worldwide and surpassed $1.7 billion in the U.S.
 Warner-Lambert is a worldwide company devoted to discovering, developing, manufacturing and marketing quality health care and consumer products. It employs approximately 34,000.
 -0- 11/3/93
 /CONTACT: Peter Wolf, 201-540-6696, Lisa Wilder, 201-540-2145, or Sandy Horner, 201-540-4268 (media); Stephen Mock, 201-540-6916, or Cary Rosansky, 201-540-4874 (investors), all of Warner-Lambert/
 (WLA)


CO: Warner-Lambert Company ST: New Jersey IN: MTC SU: PDT

SH -- NY050 -- 0113 11/03/93 11:35 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 3, 1993
Words:360
Previous Article:DATA SWITCH ELECTS TWO OUTSIDE BOARD MEMBERS
Next Article:AT&T INTRODUCES SECURITY SOFTWARE TO PROTECT PC DATA
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters